MedTrace Logo

Prevalence of Lidocaine Ineffectiveness in Adults With and Without ADHD

NCT03676725 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-10-06

Study results available
· View outcomes & findings →

Summary

This work will assess the prevalence in the general population of the ineffectiveness of the anesthetic Lidocaine compared to males with ADHD and females with ADHD with or without PMS.

Conditions

  • ADHD
  • PMS

Interventions

DRUG

Lidocaine gel

Lidocaine gel (0.75 g premeasured dose of Septodont 5% oral gel NDC 0362-0221-10)

Sponsors & Collaborators

  • Jacobi Medical Center

    collaborator OTHER

  • Boston Clinical Trials

    collaborator OTHER

  • PhenoSolve, LLC

    lead INDUSTRY

Principal Investigators

  • Michael Segal, MD PhD · PhenoSolve, LLC

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-08-14
Primary Completion
2020-03-01
Completion
2020-03-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03676725 on ClinicalTrials.gov